Ridgeback Biotherapeutics Company
Ridgeback and DRIVE, a not-for-profit biotechnology company wholly owned by Emory University, said April 7 the FDA approved DRIVE’s IND application to begin human clinical trials of EIDD-2801. Ridgeback and DRIVE announced their collaboration to rapidly advance EIDD-2801 into human trials in March. Ridgeback agreed to advance EIDD-2801 through clinical development and ensure that it is available during the current pandemic.
Under the collaboration, Ridgeback has exclusively licensed EIDD-2801, which has shown broad spectrum activity against influenza, SARS, MERS, chikungunya, and equine encephalitis. On March 20, Ralph Baric, PhD, at The University of North Carolina at Chapel Hill, and colleagues from there, Emery, Vanderbilt University Medical Center, and the U.S. Centers for Disease Control and Prevention posted a preprint of a study reporting that both prophylactic and therapeutic administration of EIDD-2801 in mice infected with SARS-CoV or MERS-CoV improved pulmonary function, and reduced virus titer and body weight loss.
In addition to COVID-19, EIDD-2801 is being developed to treat seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).
Under the collaboration, Ridgeback has exclusively licensed EIDD-2801, which has shown broad spectrum activity against influenza, SARS, MERS, chikungunya, and equine encephalitis. On March 20, Ralph Baric, PhD, at The University of North Carolina at Chapel Hill, and colleagues from there, Emery, Vanderbilt University Medical Center, and the U.S. Centers for Disease Control and Prevention posted a preprint of a study reporting that both prophylactic and therapeutic administration of EIDD-2801 in mice infected with SARS-CoV or MERS-CoV improved pulmonary function, and reduced virus titer and body weight loss.
In addition to COVID-19, EIDD-2801 is being developed to treat seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).
Technology:
COVID
Industry:
Treatments
Headquarters:
United States
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership